CITIUS ONCOLOGY, INC. (CTOR): Nasdaq/NYSE listing notice — Citius Oncology receives Nasdaq deficiency notice for bid price below $1.00

CITIUS ONCOLOGY, INC.

Nasdaq notified Citius Oncology that its common stock bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until October 20, 2025) to regain compliance with the Bid Price Rule.
If stock closes at $1.00 or more for ten consecutive business days, Nasdaq will confirm compliance.
If not compliant by October 20, 2025, the Company may be eligible for an additional 180-day period, subject to conditions.
Company is evaluating options, including a potential reverse stock split, to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CITIUS ONCOLOGY, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 23, 2025, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until October 20, 2025, to regain compliance with the Bid Price Rule. If at any time before October 20, 2025, the bid

View on SEC.gov

Browse all listing & compliance notices →

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-035575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.